newsfilter
← Latest News
Business Wire·

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

Expanded coverage, supported by published data from the Vall d'Hebron Institute of Oncology (VHIO), enables Medicare beneficiaries receiving immunotherapy to access ultrasensitive MRD testing to monitor treatment